Noramco is the global leader in developing and manufacturing pharmaceutically-produced cannabinoid APIs. Our portfolio includes Cannabidiol, Dronabinol, Nabilone, as well as various phytocannabinoids partnered with extensive offerings of degradants, metabolites and analytical reference standards.
Ultra-high purity materials (low ppm THC in CBD) are designed for brand and generic dosage form lifecycles, through clinical stages to scaled commercial production. GMP manufacturing in USA and Europe, provides true global supply chain reach to our expanding customer base.
Verdemed’s mission is to offer the best of approved existing and prospective cannabinoid products to all Latin Americans, in all countries, in all jurisdictions legally authorized to sell medical cannabis. The company’s initial focus is on product formulations of cannabinoid pharmaceuticals currently available in Canada, Europe, and the USA. Verdemed aims to meet Latin America’s medical needs with similar products and medical cannabis treatments approved by Health Canada, EMA, and the USA FDA